|1.||Mantis, Nicholas J: 8 articles (12/2015 - 04/2006)|
|2.||Pincus, Seth H: 5 articles (06/2015 - 12/2002)|
|3.||Vitetta, Ellen S: 5 articles (01/2012 - 06/2002)|
|4.||Wong, John: 5 articles (07/2009 - 01/2005)|
|5.||Chen, Zhi-Kui: 4 articles (01/2013 - 08/2009)|
|6.||Lin, Li-Wu: 4 articles (01/2013 - 08/2009)|
|7.||Lord, J Michael: 4 articles (01/2012 - 01/2005)|
|8.||Roberts, Lynne M: 4 articles (01/2012 - 01/2003)|
|9.||Spooner, Robert A: 4 articles (01/2012 - 01/2003)|
|10.||Griffiths, Gareth D: 4 articles (11/2011 - 01/2003)|
01/01/1984 - "Should these approaches prove to be effective in only a fraction of cases, combination in vitro treatment or the use of more efficient effector mechanisms for cell killing (e.g., ricin conjugated antibody) may very well clear occult tumor from the marrow of most patients. "
05/01/2007 - "To develop a novel ricin-based approach for the safe and effective therapy of cancer. "
04/01/1993 - "Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms."
02/01/1992 - "Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion."
11/01/1985 - "These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates."
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/01/2015 - "SBDS assesses the integrity of the peptidyl (P) site, bridging uL16 (mutated in T-cell acute lymphoblastic leukemia) with uL11 at the P-stalk base and the sarcin-ricin loop. "
02/01/1999 - "Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells."
03/15/1993 - "The efficacy of anti-B4-blocked ricin in vivo was assessed in survival models of SCID mice bearing either a human B-cell lymphoma (Namalwa), a human non-T and non-B acute lymphoblastic leukemia (Nalm-6), or a murine B-cell lymphoma transfected with the human CD19 gene (300B4). "
04/01/1987 - "The monoclonal antibody PHM-6, which is specific for the common acute lymphoblastic leukemia antigen (CALLA), was conjugated to the plant toxin ricin. "
04/01/1987 - "Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA)."
|3.||Neoplasm Metastasis (Metastasis)
01/01/1992 - "Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases."
01/01/1992 - "Adoptive transfer experiments showed that ricin-treated LAK cells were significantly more efficient than untreated LAK cells in inhibiting M4- but not F1-induced lung metastases. "
01/01/1992 - "Ricin treatment did not alter the tissue distribution of intravenously (i.v.) injected LAK cells, which selectively localized in the lung early after inoculation, whether or not metastases were present. "
01/01/1992 - "As transferred cells preferentially locate in the lung, we studied the therapeutic effect of ricin-loaded, lymphokine-activated killer (LAK) cells on lung metastases induced by M4 or B16-F1 (F1) tumour cell injection. "
12/15/1982 - "The ricin-resistant cells (ricinR) and the wheat-germ agglutinin-resistant (WGAR) cells, both of which showed reduced hematogenous metastases in vivo, showed reduced adhesiveness specifically to endothelial cells and extracellular matrices. "
10/01/1994 - "The MAbs neutralized ricin in vitro in an EL-4 mouse leukemia cell assay and in an in vivo mouse model. "
01/01/1989 - "[Selective elimination of human T-leukemia cells with the use of a conjugate of the A-chain of ricin and a monoclonal antibody against CD5-antigen of T-lymphocytes]."
08/15/1988 - "The conjugates of SN5 and SN6 with ricin A-chain (RA) showed specific activity against the leukemia cells but not against control cells in an in vitro assay. "
02/10/1982 - "In this paper, it is shown that the addition of A chain to mouse leukemia cells (AKR SL3) after the cells were first reacted with purified ricin B chain also results in efficient inhibition of protein synthesis. "
11/15/1978 - "The results warrant exploration of the use of ricin in the treatment of human leukemia."
|5.||Hodgkin Disease (Hodgkin's Disease)
01/01/1998 - "The data of a closed phase I/II trial in patients with resistant Hodgkin's lymphoma indicate promising results using a chemically linked anti-CD25 ricin-A immunotoxin (IT) (RFT5-SMPT-dgA). "
08/01/1998 - "Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma."
01/15/1997 - "A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma."
05/01/2009 - "The purpose of this work was to compare the pathways of cell death induced by the RIP saporin with those carried out by ricin in the L540 human Hodgkin's lymphoma-derived cell line. "
05/01/2003 - "Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma."
|4.||Antineoplastic Agents (Antineoplastics)
|8.||Immunoglobulin G (IgG)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Drug Therapy (Chemotherapy)